Dataset from A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of 100mg Twice Daily Oral Dosing of Midostaurin Administered to Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease

The purpose of this study was to determine the efficacy and safety of twice daily (bid) oral midostaurin in patients with Aggressive Systemic Mastocytosis (ASM) or Mast Cell Leukemia (MCL) with or without an Associated Hematological clonal Non-Mast cell lineage Disease (AHNMD).

本研究旨在评估每日两次（bid）口服米哚妥林（midostaurin）治疗伴或不伴伴发造血克隆性非肥大细胞系疾病（Associated Hematological clonal Non-Mast cell lineage Disease, AHNMD）的侵袭性系统性肥大细胞增多症（Aggressive Systemic Mastocytosis, ASM）或肥大细胞白血病（Mast Cell Leukemia, MCL）患者的有效性与安全性。